Lung Cancer

Lung cancer advocate Katie shares how losing her father to the disease and her own cancer journey inspire her work with LiveLung today.

At least half of patients get nervous before a follow-up scan. Dr. Geoffrey Pelz explains why that is common, what he wants patients to hear at the first visit and how much lung cancer treatment has shifted in 15 years.

An incidental CT scan revealed stage 1A lung cancer. After robotic surgery at Hackensack University Medical Center, Carolyn Rothfeld describes a recovery that took longer than she expected.

After receiving a stage 1 lung cancer diagnosis, Carolyn Rothfeld underwent robotic surgery to remove part of her lung and is back to her exercise routine nine months later.

Diagnosed with stage 1 lung cancer at 40, Gillian Ryan shares the overwhelming guilt she felt about bringing cancer into her family’s life.

Diagnosed with limited-stage small-cell lung cancer, Tammy shares how treatment progress and a mindset shift helped her find hope.

Heather Prather shares her stage 4 non small cell lung cancer journey, finding hope, joy and support through the LiveLung community and cancer advocacy.

Biomarker testing looks for genes, proteins and other markers in your cancer that can help your care team choose the most effective treatment for you.

As Canadian wildfire smoke blankets much of the U.S., here's what people with cancer and cancer survivors should know about the potential health risks.

After reaching remission from stage 3B non-small cell lung cancer, one survivor shares the emotional journey of healing, hope and finding a new normal.

Join LiveLung's Charlotte meeting to learn how The White Ribbon Project is raising lung cancer awareness, reducing stigma and supporting patients.

AURORA, a phase 3 trial, is testing aglatimagene besadenovec plus Keytruda in patients with lung cancer who progressed on immunotherapy.

A kidney cancer survivor reflects on National Doctors Day and how trust with his oncologist, Dr. Toni Choueiri, became a lifelong bond.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.

Study data shows Ibtrozi provides rapid symptom relief and stable brain health for patients with advanced ROS1-positive lung cancer.

Patients with EGFR exon 20-positive NSCLC had longer progression-free survival with Zegfrovy than chemotherapy.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

A lung and breast cancer survivor shares how genetic history, supporting her daughter and leading a support group helped her keep smiling.

A SEER-Medicare study found nearly half of older patients with metastatic non–small cell lung cancer never received systemic therapy.

Logan Terry, who has stage 4 ALK-positive lung cancer, encouraged patients with cancer to keep living fully after diagnosis and not be defined by fear or bitterness.

New therapies are beginning to crack KRAS, offering tumor shrinkage and longer survival as researchers work to overcome resistance.

KRAS was long thought undruggable in cancer until scientists discovered a hidden binding pocket in mutant KRAS, leading to targeted therapies.

New T-cell engagers and ADCs show survival gains in pretreated small cell lung cancer, signaling long-awaited progress and more treatment options for patients.